Studienfinder
| Acronym | VERSUS | |
|---|---|---|
| AUO Nr. | AU 01/21 | |
| Registernummer | DRKS00015762 | |
| Titel: | Verbesserung der Versorgungsqualität urologischer Tumorerkrankungen durch standardisierte Dokumentation – die VERSUS-Studie von d-uo | |
| Organ: | Blase, Hoden, Niere, Penis, Prostata | |
| Phase: | Versorgungsforschung | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | DePeCa-1 | |
| AUO Nr. | PE 02/25 | |
| Registernummer | NCT07110038 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma | |
| Organ: | Penis | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | CARAT | |
| AUO Nr. | AU 03/25 | |
| Registernummer | NCT03374267 (Infos auf ClinicalTrials.gov) | |
| Titel: | Clinical Research Platform on Urologic Cancer Treatment and Outcome (Registry Platform Urologic Cancer; CARAT) | |
| Organ: | Blase, Niere | |
| Phase: | Beobachtung/Register | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | CoRe_CC3 | |
| AUO Nr. | PE 04/25 | |
| Registernummer | NCT05999396 (Infos auf ClinicalTrials.gov) | |
| Titel: | FIHl trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with solid cancer | |
| Organ: | Penis | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | OligoRARE | |
| AUO Nr. | AU 07/26 | |
| Registernummer | NCT04498767 (Infos auf ClinicalTrials.gov) | |
| Titel: | Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial | |
| Organ: | Blase, Niere | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | STELLAR-002 | |
| AUO Nr. | AU 12/26 | |
| Registernummer | NCT05176483 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors | |
| Organ: | Blase, Niere, Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | RAISN | |
| AUO Nr. | AH 19/25 | |
| Registernummer | DRKS00031749/NCT06144736 | |
| Titel: | Robotisch-assistierte Bild-gesteuerte Sentinel node Biopsie (Englisch „robotic-assisted image-guided sentinel node biopsy“) bei Hodentumorpatienten | |
| Organ: | Hoden | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PRIMETEST II | |
| AUO Nr. | AH 20/25 | |
| Registernummer | NCT06144736 + DRKS00031749 (Infos auf ClinicalTrials.gov) | |
| Titel: | Phase-II-Studie zur prospektiven Prüfung neuer prädiktiver Risikofaktoren für ein Rezidiv bei Patienten mit Seminom im klinischen Stadium II A/B nach primärer roboter-assistierter retrperitonealer Lymphknotendissektion (RA-RPLND) | |
| Organ: | Hoden | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | BNT211-01 | |
| AUO Nr. | AH 21/25 | |
| Registernummer | NCT04503278 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors | |
| Organ: | Hoden | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PROHEAR | |
| AUO Nr. | AH 22/25 | |
| Registernummer | NCT06521190 (Infos auf ClinicalTrials.gov) | |
| Titel: | Multizentrische, placebokontrollierte Split-Body-Studie zur otoprotektiven Wirkung des Kv7.4-Activators ACOU085 bei Cisplatin-induzierter Ototoxizität | |
| Organ: | Hoden | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | LITESPARK-033 | |
| AUO Nr. | AN 68/25 | |
| Registernummer | - | |
| Titel: | A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib for the Treatment of Participants with Locally Advanced or Metastatic RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy | |
| Organ: | Niere | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | Thuroc | |
| AUO Nr. | AB 81/21 | |
| Registernummer | - | |
| Titel: | Nicht-interventionelle, prospektive Versorgungsforschungsstudie (THUROC-Studie) von d-uo zur intravesikalen Instillation von Mitomycin C beim nicht-muskelinvasiven Harnblasenkarzinom | |
| Organ: | Blase | |
| Phase: | Versorgungsforschung | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | Trophy-01 | |
| AUO Nr. | AB 90/23 | |
| Registernummer | NCT03547973 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer | |
| Organ: | Blase | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | INTerpath-005 | |
| AUO Nr. | AB 91/23 | |
| Registernummer | NCT06305767 (Infos auf ClinicalTrials.gov) | |
| Titel: | Eine randomisierte, doppelblinde, placebo- und wirkstoffvergleichskontrollierte klinische Studie der Phase 2 mit adjuvantem V940 (mRNA-4157) plus Pembrolizumab gegenüber adjuvantem Placebo plus Pembrolizumab bei Teilnehmern mit muskelinvasivem Hochrisiko-Urothelkarzinom nach radikaler Resektion | |
| Organ: | Blase | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | Keynote-365 Kohorten E-J | |
| AUO Nr. | AP 94/16 | |
| Registernummer | NCT02861573 (Infos auf ClinicalTrials.gov) | |
| Titel: | Phase-Ib/II-Studie zur Kombinationstherapien mit Pembrolizumab (MK-3475) bei Patienten mit mCRPC | |
| Organ: | Prostata | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | UroNAT | |
| AUO Nr. | AB 94/24 | |
| Registernummer | DRKS00026204 | |
| Titel: | Nationales Register Urothelkarzinom zur Erfassung und Verbesserung der sektorenübergreifenden Versorgungsqualität | |
| Organ: | Blase | |
| Phase: | Versorgungsforschung | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | SunRISe-5 | |
| AUO Nr. | AB 95/25 | |
| Registernummer | -NCT06211764 | |
| Titel: | Eine randomisierte, offene, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von TAR-200 gegenüber einer intravesikalen Chemotherapie nach Wahl des Prüfers bei Teilnehmern, die mit Bacillus Calmette-Guérin (BCG) behandelt wurden und ein Rezidiv mit hohem Risiko nicht-muskelinvasivem Blasenkrebs (HR-NMIBC) und die für eine radikale Zystektomie nicht in Frage kommen oder sich dagegen entscheiden. | |
| Organ: | Blase | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | INTerpath-011 | |
| AUO Nr. | AB 97/25 | |
| Registernummer | NCT06833073 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer | |
| Organ: | Blase | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ||
| AUO Nr. | AB 103/25 | |
| Registernummer | NCT05316155 (Infos auf ClinicalTrials.gov) | |
| Titel: | Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer | |
| Organ: | Blase | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | FORAGER-1 | |
| AUO Nr. | AB 104/25 | |
| Registernummer | NCT05614739 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase 1, Open-Label, Multicenter Study of LY3866288 in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations | |
| Organ: | Blase | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | INSIGHT | |
| AUO Nr. | AB 105/25 | |
| Registernummer | NCT03252938 (Infos auf ClinicalTrials.gov) | |
| Titel: | An Explorative, Open-labeled, Phase I Study to Evaluate the Feasibility and the Safety of IMP321 in Combination With Immunotherapeutic/Targeted/Chemotherapeutic Agents or Via New Routes of Application in Advanced Stage Solid Tumors | |
| Organ: | Blase | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ENLIGHTED | |
| AUO Nr. | AB 106/25 | |
| Registernummer | NCT04620239 (Infos auf ClinicalTrials.gov) | |
| Titel: | Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer | |
| Organ: | Blase | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PRACTICE | |
| AUO Nr. | AB 107/25 | |
| Registernummer | NCT06806059 (Infos auf ClinicalTrials.gov) | |
| Titel: | Prospektiv randomisierte Interventionsstudie zur Untersuchung der präoperativen körperlichen Aktivität auf die perioperative Morbidität nach radikaler Zystektomie | |
| Organ: | Blase | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | MoonRISe-3 | |
| AUO Nr. | AB 108/25 | |
| Registernummer | NCT06919965 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG) | |
| Organ: | Blase | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | P-EVOLUTION | |
| AUO Nr. | AB 110/25 | |
| Registernummer | NCT06657157 (Infos auf ClinicalTrials.gov) | |
| Titel: | Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab As First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma | |
| Organ: | Blase | |
| Phase: | NIS | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | TROPION-Urothelial03 (TU03) | |
| AUO Nr. | AB 111/26 | |
| Registernummer | NCT07129993 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment | |
| Organ: | Blase | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | IZABRIGHT-Bladder01 | |
| AUO Nr. | AB 113/26 | |
| Registernummer | NCT07106762 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment | |
| Organ: | Blase | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | TestoVer | |
| AUO Nr. | AP 118/21 | |
| Registernummer | DRKS00009995 | |
| Titel: | Nicht-interventionelle, prospektive Versorgungsforschungsstudie von d-uo zur androgendeprivativen Therapie (ADT) von Patienten mit einem Prostatakarzinom unter besonderer Berücksichtigung des Testosteronspiegels (TestoVer-Studie) | |
| Organ: | Prostata | |
| Phase: | Versorgungsforschung | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | OMAHA-003 | |
| AUO Nr. | AP 123/23 | |
| Registernummer | NCT06136624 (Infos auf ClinicalTrials.gov) | |
| Titel: | Eine randomisierte, offene Phase-III-Studie zu MK-5684 im Vergleich zu Abirateronacetat oder Enzalutamid bei Teilnehmern mit mteastasiertem kastrationsresistentem Prostatakarzinom (mCRPC), die zuvor mit einer Next-Generation-Hormontherapie (NHA) und taxanbasierter Chemoterhapie behandelt wurden | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | OMAHA-004 | |
| AUO Nr. | AP 124/23 | |
| Registernummer | NCT06136650 (Infos auf ClinicalTrials.gov) | |
| Titel: | Eine randomisierte, offene Phase-III-Studie zu MK-5684 im Vergleich zu alternativem Abirateronacetat oder Enzalutamid bei Teilnehmern mit metastasiertem kastrationsrestistentem Prostatakarzinom (mCPRC), das während oder nach voerhergehender Behandlung mit einer Next-Generation-Hormontherapie (NHA) fortgeschritten ist | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | NEPI | |
| AUO Nr. | AP 125/23 | |
| Registernummer | NCT06388369 (Infos auf ClinicalTrials.gov) | |
| Titel: | Eine randomisierte Phase-I/II-Studie zur neoadjuvanten Therapie mit 177-Lutetium-PSMA-617 mit oder ohne Ipilimumab bei Patienten mit einem Höchst-Risiko Prostatakarzinom, die Kandidaten für eine radikale Prostatektomie sind (NEPI-Trial) | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PROceed | |
| AUO Nr. | AP 128/23 | |
| Registernummer | NCT06380738 (Infos auf ClinicalTrials.gov) | |
| Titel: | Eine prospektive, nicht-interventionelle Studie zur Untersuchung der klinischen Daten und Charakteristika von Patienten mit metastasiertem kastrationsresistentem Prostatakrebs (mCRPC), die in Deutschland mit Olaparib+Abirateron unter realen Bedingungen behandelt werden | |
| Organ: | Prostata | |
| Phase: | NIS | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ProSTone | |
| AUO Nr. | AP 129/23 | |
| Registernummer | NCT04271579 (Infos auf ClinicalTrials.gov) | |
| Titel: | Prostatakarzinomrezidiv mit PSMA PET positiver einseitig-pelviner Metastasierung: ist die einseitige Salvage Lymphadenektomie ausreichend? (ProSTone) | |
| Organ: | Prostata | |
| Phase: | Operative Studie | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ProSperA | |
| AUO Nr. | AP 130/23 | |
| Registernummer | NCT05646550 (Infos auf ClinicalTrials.gov) | |
| Titel: | Erstanwendungsstudie zur Untersuchung der Sicherheit, Verträglichkeit und vorläufigen Wirksamkeit des bispezifischen PSMAxCD3-Antikörpers CC-in Männern mit biochemischem Rezidiv (BCR) eines Prostatakarzinoms (PC) | |
| Organ: | Prostata | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | EvoPar-Prostate01 | |
| AUO Nr. | AP 131/23 | |
| Registernummer | NCT06120491 (Infos auf ClinicalTrials.gov) | |
| Titel: | Randomisierte, doppelblinde, placebokontrollierte 2-Kohortenstudie der Phase-III-Studie von AZD5305 in Kombination mit neuen hormonellen Wirkstoffen nach Wahl des Prüfers/ der Prüferin bei Patienten mit HRRm und nicht-HRRm-metastasiertem, kastrationssensitivem Prostatakarzinom | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ProNAT | |
| AUO Nr. | AP 133/24 | |
| Registernummer | DRKS00030737 | |
| Titel: | Nationales Register Prostatakarzinom zur Erfassung und Verbesserung der sektorenübergreifenden Versorgungsqualität | |
| Organ: | Prostata | |
| Phase: | Versorgungsforschung | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | OMAHA-01A | |
| AUO Nr. | AP 134/25 | |
| Registernummer | NCT06353386 (Infos auf ClinicalTrials.gov) | |
| Titel: | MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | rechARge | |
| AUO Nr. | AP 135/25 | |
| Registernummer | NCT06764485 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | IDeate-Prostate01 | |
| AUO Nr. | AP 138/25 | |
| Registernummer | NCT06925737 (Infos auf ClinicalTrials.gov) | |
| Titel: | ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | AMG-509 | |
| AUO Nr. | AP 139/25 | |
| Registernummer | NCT06613100 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | IDeate-Prostate02 | |
| AUO Nr. | AP 141/25 | |
| Registernummer | NCT06863272 (Infos auf ClinicalTrials.gov) | |
| Titel: | MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | KiRi | |
| AUO Nr. | AP 142/25 | |
| Registernummer | NCT06720532 (Infos auf ClinicalTrials.gov) | |
| Titel: | Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study | |
| Organ: | Prostata | |
| Phase: | Beobachtung/Register | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PSMACare | |
| AUO Nr. | AP 143/25 | |
| Registernummer | NCT05849298 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | |
| Organ: | Prostata | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | MEVPRO-1 | |
| AUO Nr. | AP 144/25 | |
| Registernummer | NCT06551324 (Infos auf ClinicalTrials.gov) | |
| Titel: | Eine randomisierte, offene, Studie der Phase 3 zu PF-06821497 (Mevrometostat) in Kombination mit Enzalutamid im Vergleich zu Enzalutamid oder Docetaxel bei Teilnehmern mit metastasiertem, kastrationsresistentem Prostatakarzinom (mCRPC) nach Vorbehandlung mit Abirateron | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | MEVPRO-2 | |
| AUO Nr. | AP 145/25 | |
| Registernummer | NCT06629779 (Infos auf ClinicalTrials.gov) | |
| Titel: | Eine randomisierte, doppelblinde, Placebo-kontrollierte Studie der Phase 3 zu PF-06821497 (Mevrometostat) in Kombination mit Enzalutamid als Erst- oder Zweitlinientherapie bei Teilnehmern mit metastasiertem, kastrationsresistentem Prostatakarzinom (mCRPC) nach Vorbehandlung mit Abirateron | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PSMAreal | |
| AUO Nr. | AP 147/25 | |
| Registernummer | NCT06517719 (Infos auf ClinicalTrials.gov) | |
| Titel: | Real-world Experience With Lutetium (177Lu) Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer, an Observational, Multicenter, Prospective Cohort Study | |
| Organ: | Prostata | |
| Phase: | Phase IV | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ARASTEP | |
| AUO Nr. | AP 149/25 | |
| Registernummer | NCT05794906 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | EAGLE-i | |
| AUO Nr. | AP 152/25 | |
| Registernummer | NCT06122584 (Infos auf ClinicalTrials.gov) | |
| Titel: | Prospective, Multi-Center Study to Assess the Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | X-SMILE | |
| AUO Nr. | AP 154/25 | |
| Registernummer | NCT06834152 (Infos auf ClinicalTrials.gov) | |
| Titel: | Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | STAMPEDE2 | |
| AUO Nr. | AP 155/25 | |
| Registernummer | NCT06320067 (Infos auf ClinicalTrials.gov) | |
| Titel: | Studying Treatments in Patients Receiving Androgen Deprivation Therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and Radiation Efficacy: A 2nd Multi-arm Multi-stage Randomised Controlled Trial | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PSMAxCD3 | |
| AUO Nr. | AP 156/25 | |
| Registernummer | NCT04104607 (Infos auf ClinicalTrials.gov) | |
| Titel: | First in Human Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma | |
| Organ: | Prostata | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PYNNACLE | |
| AUO Nr. | AP 157/36 | |
| Registernummer | NCT04585750 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | OMNIRAY | |
| AUO Nr. | AP 158/25 | |
| Registernummer | NCT07114601 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors | |
| Organ: | Prostata | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | XALute | |
| AUO Nr. | AP 159/25 | |
| Registernummer | NCT06691984 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | - neu - | |
| AUO Nr. | AP 163/25 | |
| Registernummer | NCT07047118 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Lutetium (177Lu) Vipivotide Tetraxetan in Adult Male Patients With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) | |
| Organ: | Prostata | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PSMA-DC | |
| AUO Nr. | AP 164/25 | |
| Registernummer | NCT05939414 | |
| Titel: | An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC) | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | E - neu - | |
| AUO Nr. | AP 165/25 | |
| Registernummer | NCT05803941 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase IV | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | REALITY | |
| AUO Nr. | AP 166/25 | |
| Registernummer | NCT04833517 (Infos auf ClinicalTrials.gov) | |
| Titel: | Analysis of a Prospective REgistry to Assess Outcome and Toxicity of Targeted RadionucLide TherapY in Patients With mCRPC in Clinical Routine | |
| Organ: | Prostata | |
| Phase: | Phase IV | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | LOOPS | |
| AUO Nr. | AP 167/26 | |
| Registernummer | NCT07118436 (Infos auf ClinicalTrials.gov) | |
| Titel: | Liquid Biopsy as a Biomarker in Patients Treated With PSMA Radioligand Therapy | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | REFINE | |
| AUO Nr. | AP 168/26 | |
| Registernummer | NCT06859203 (Infos auf ClinicalTrials.gov) | |
| Titel: | Prospective Evaluation of Fluciclovine (18F) PET/CT in Patients with Prior Negative PSMA PET/CT | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ImmunBioProBrachy | |
| AUO Nr. | AP 169/26 | |
| Registernummer | NCT07131956 (Infos auf ClinicalTrials.gov) | |
| Titel: | Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ||
| AUO Nr. | AP 170/26 | |
| Registernummer | NCT06820333 (Infos auf ClinicalTrials.gov) | |
| Titel: | Der klinische Einfluss und prognostische Wert von [18F]PSMA-1007 Bildgebung für das Primärstaging des Prostatakarzinoms: Real-World-Evidence aus einer monozentrischen, prospektive Beobachtungsstudie | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PROMISE-PET | |
| AUO Nr. | AP 171/26 | |
| Registernummer | NCT06320223 (Infos auf ClinicalTrials.gov) | |
| Titel: | Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | - neu - | |
| AUO Nr. | AP 172/26 | |
| Registernummer | NCT06657131 (Infos auf ClinicalTrials.gov) | |
| Titel: | Diagnostische Genauigkeit von 18F-PSMA-1007 bei Lokalrezidiven im Kontext des biochemischen Rezidivs: Real-World-Evidence aus einer monozentrischen, prospektiven Beobachtungs-studie | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | NICE-PSMA | |
| AUO Nr. | AP 174/26 | |
| Registernummer | NCT07129551 (Infos auf ClinicalTrials.gov) | |
| Titel: | Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | RADIODOSE | |
| AUO Nr. | AP 175/26 | |
| Registernummer | NCT06531499 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase I, Open-label, Multi-center Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PAROS | |
| AUO Nr. | AP 176/26 | |
| Registernummer | NCT04083937 (Infos auf ClinicalTrials.gov) | |
| Titel: | Prostate Cancer Patients Treated With Alternative Radiation Oncology Strategies | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PrähabPro | |
| AUO Nr. | AP 177/26 | |
| Registernummer | NCT07156903 (Infos auf ClinicalTrials.gov) | |
| Titel: | Qualitative Erhebung Zur Erfassung Der Bedürfnisse Von Patienten Und Deren Angehörigen während Und Nach Einer Strahlentherapie Bei Prostatakarzinomerkrankung Und Deren Einstellung Und Wünsche bezüglich Einer Prähabilitationsmaßnahme | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ARTIA-Prostate | |
| AUO Nr. | AP 178/26 | |
| Registernummer | NCT05804318 (Infos auf ClinicalTrials.gov) | |
| Titel: | Daily Adaptive Stereotactic Body Radiation Therapy for Prostate Cancer With Urethral Sparing: A Prospective Trial Using an Individualized Approach to Reduce Urinary Toxicity | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | FOKAL-BT | |
| AUO Nr. | AP 179/26 | |
| Registernummer | NCT02391051 (Infos auf ClinicalTrials.gov) | |
| Titel: | Focal Brachytherapy in Patients With Selected ””Low-risk”” Prostate Cancer - a Phase-II-trial | |
| Organ: | Prostata | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | HYPOSTAT-III | |
| AUO Nr. | AP 180/26 | |
| Registernummer | NCT06914544 (Infos auf ClinicalTrials.gov) | |
| Titel: | Hypofractionated Radiosurgery for Localised Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ultraHART | |
| AUO Nr. | AP 181/26 | |
| Registernummer | NCT06355050 (Infos auf ClinicalTrials.gov) | |
| Titel: | Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | HETERERO | |
| AUO Nr. | AP 182/26 | |
| Registernummer | NCT04889742 (Infos auf ClinicalTrials.gov) | |
| Titel: | Radiotherapy in Combination With Pembrolizumab in Patients With PSA Persistence or Biochemical Recurrence After Radical Prostatectomy Due to Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ||
| AUO Nr. | AP 183/26 | |
| Registernummer | NCT06991556 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | |
| Organ: | Prostata | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ||
| AUO Nr. | AP 185/26 | |
| Registernummer | NCT04794699 (Infos auf ClinicalTrials.gov) | |
| Titel: | An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors | |
| Organ: | Prostata | |
| Phase: | Phase I | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ProbeTILity | |
| AUO Nr. | AP 186/26 | |
| Registernummer | NCT07255664 (Infos auf ClinicalTrials.gov) | |
| Titel: | A FIH, Phase I/IIa, Open-label Trial Assessing Safety, Tolerability, and Feasibility of Repeated Administrations of a Novel Autologous TIL-based Immunotherapy in Patients With Metastatic Colorectal or Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | EvoPar-PRO2 | |
| AUO Nr. | AP 187/26 | |
| Registernummer | - | |
| Titel: | A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ||
| AUO Nr. | AP 188/26 | |
| Registernummer | NCT07005154 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | TulmiSTAR-02 | |
| AUO Nr. | AP 190/26 | |
| Registernummer | NCT07206056 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination With Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination With Darolutamide Versus Darolutamide Alone in Patients With Metastatic Hormone-sensitive Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | TulmiSTAR-01 | |
| AUO Nr. | AP 191/26 | |
| Registernummer | NCT07206056 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | DARO-DUB | |
| AUO Nr. | AP 192/26 | |
| Registernummer | NCT07395804 (Infos auf ClinicalTrials.gov) | |
| Titel: | DAROlutamide DoUBlet Therapy in Daily Practice (DARO-DUB) - Real-world Evaluation of Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Treated With Darolutamide Plus ADT in Germany | |
| Organ: | Prostata | |
| Phase: | NIS | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | Luxar-03 | |
| AUO Nr. | AP 193/26 | |
| Registernummer | NCT07226986 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | BET-PSMA-121 | |
| AUO Nr. | AP 194/26 | |
| Registernummer | NCT05413850 (Infos auf ClinicalTrials.gov) | |
| Titel: | An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | REINFORCE | |
| AUO Nr. | AP 195/26 | |
| Registernummer | NCT07333066 (Infos auf ClinicalTrials.gov) | |
| Titel: | Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide | |
| Organ: | Prostata | |
| Phase: | Phase III | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ARISTA | |
| AUO Nr. | AP 198/26 | |
| Registernummer | NCT06822036 (Infos auf ClinicalTrials.gov) | |
| Titel: | Prospective Randomized Controlled Trial Evaluating the Efficacy of Intraoperative ARISTA™ AH Polysaccahride Application on the Postoperative Blood Loss in Patients Undergoing Robotic Assisted Radical Prostatectomy for the Treatment of Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | ZMoveMent-1 | |
| AUO Nr. | AP 199/26 | |
| Registernummer | NCT07126860 (Infos auf ClinicalTrials.gov) | |
| Titel: | Z - neu - | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | PROCARE | |
| AUO Nr. | AP 201/26 | |
| Registernummer | NCT06835218 (Infos auf ClinicalTrials.gov) | |
| Titel: | PROstate CAncer Real World Evidence Registry: RECURRENT AND METASTATIC PROSTATE CANCER | |
| Organ: | Prostata | |
| Phase: | Versorgungsforschung | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | RegisterPROS | |
| AUO Nr. | AP 202/26 | |
| Registernummer | NCT06872619 (Infos auf ClinicalTrials.gov) | |
| Titel: | A Registry for Prostate Cancers | |
| Organ: | Prostata | |
| Phase: | keine | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||
| Acronym | R - neu - | |
| AUO Nr. | AP 203/26 | |
| Registernummer | NCT06807359 (Infos auf ClinicalTrials.gov) | |
| Titel: | Open-label Clinical Phase 1/2 Study to Assess the Safety and Efficacy of the SpectraCure P18 System and Verteporfin for Injection for the Treatment of Primary Localized Prostate Cancer | |
| Organ: | Prostata | |
| Phase: | Phase I/II | |
| Status: | aktiv/Rekrutierung offen | |
| -> Details zur Studie | ||